Agoracom Blog Home

Posts Tagged ‘Innocan’

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 5:36 PM on Friday, September 25th, 2020
Innocan-Blog

(INNO:CSE)

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

WHY INNOCAN?

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
  • Separate breakthrough delivery and control release technology that enables the injection of CBD.

CONSUMER RETAIL – DERMA COSMETICS 

Completed Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements – Europe and United States
  • Manufacturing Has Commenced For 9 Products As Of Q2 2020
  • Distribution Agreements – United Kingdom and Ireland

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commenced In H2 2020 during September

SEEING IS BELIEVING

FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.

VIDEO: Innocan $INNO.ca Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) #CBD Premium Facial Serum on Skin Hydration $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 12:15 PM on Wednesday, September 16th, 2020
Innocan-Blog

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) on skin hydration.

  • Study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”.
  • The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin.
  • The results demonstrated that there were significant hydration increases for each period.
  • The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.

In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.

Read Full Release

CEO SPOTLIGHT: Iris Bincovich, CEO of Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:52 PM on Tuesday, September 15th, 2020
Innocan-Blog

Hub On AGORACOM / Corporate Profile

Innocan Phrama $INNO.ca Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:07 PM on Tuesday, September 15th, 2020
Innocan-Blog
  • Completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol on skin hydration
  • Results demonstrated that there were significant hydration increases for each period
  • The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study

Herzliya, Israel and Calgary, Alberta–(September 15, 2020) –   Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) (the “Serum”) on skin hydration.

The study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”. The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin. The results demonstrated that there were significant hydration increases for each period. The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.

In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.

“The results of these studies have demonstrated the efficacy of the SHIR ™ Premium CBD Facial Serum product. Hydrating the skin is one of the most crucial measures to keep the skin healthy, young and also to eliminate wrinkles. The amazing results of the new clinical studies are in addition to Innocan’s research and development efforts to bring to market, a trustworthy product that will set a new industry standard, stated Iris Bincovich, Chief Executive Officer of Innocan.”

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/63880_98aa5e38b4389924_003full.jpg

About Innocan

The Company, through its wholly owned subsidiary, Innocan Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

InnoCan $INNO.ca developing revolutionary products that harness the unique properties of #Cannabinoids combined with smart delivery formulations $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, September 8th, 2020
Innocan-Blog

Iris Bincovich, CEO of InnoCan Pharma Corp, shares with Cannabis Report World an overview on how they are disrupting the cannabis world through pharmaceutical innovation and gives us a preview of some of their latest projects one of which is targeting the COVID-19 virus.

Can you introduce us to InnoCan? Where did the idea for the concept originate from?

InnoCan Pharma Corporation is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals.

The founders and officers of InnoCan, all have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

InnoCan Pharma was established by Yoram Drucker, an Israeli serial entrepreneur with experience of founding companies in the field of stem cells; Ron Mayron Former CEO of Teva Israel. Teva Pharmaceutical is one of the largest generic drug producers in the world; Nir Avram, our topicals formulator, who was on the pharmaceutical innovation team at Perrigo, he holds a number of patents and has more than 30 years of experience developing topicals; and I bringing a world-wide experience in healthcare with nearly 20 years of international marketing, business development and sales experience. I have led and managed hundreds of successful international transactions in the OTC, cosmetics and dermatology sector.

InnoCan was established as a Pharma company, to enhance the therapeutic properties of CBD, developing unique synergistic delivery systems and OTC/cosmetic products.

Some of our latest projects and products: InnoCan with the Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both Central Nervous System (CNS) indications and the Covid-19 Corona Virus using CBD-loaded Exosomes.

CBD-loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

In addition, InnoCan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection.

Together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, we plan to test the liposome platform on several potential indications.

InnoCan Pharma also develops and manufactures OTC products: R&G Relief & Go – a breakthrough patent-pending CBD pain relief brand, integrating CBD with other pharmaceutical ingredients.

InnoCan’s Pain relief spray provides fast action muscle relaxant and pain relief. It contains an analgesic blend of active ingredients with pure CBD to provide temporary relief of muscle and joint pain.

We also developed a line of Premium derma cosmetic CBD-integrated anti-aging product lines: SHIR, where its formulations feature a tailored blend of active ingredients and technology.

Can you tell us more about your innovative products?

1) Our latest project is a collaboration targeting the COVID-19 virus with Tel Aviv University and Professor Daniel Offen, who heads The Laboratory for Neurosciences at the Felsenstein Medical Research Center.

We are developing an inhalable treatment based on exosomes loaded with CBD, designed to target COVID-19 infected lung cells and might be applicable also to central nervous system diseases.

Exosomes have the ability to target damaged cells like a targeted missile, they improve regeneration and assist in their recovery. CBD is a known anti-inflammatory substance.

Exosomes have been studied for their cell recovery actions and inflammation targeting.  CBD-loaded exosomes (“CLX”) may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. The CBD loaded exosomes are expected to be administered by inhalation.

Together with Professor Offen, an experienced researcher on cell and gene therapy in neurodegenerative diseases, we are looking to develop a new technology that might be applicable to several indications. Prof. Offen is a co-founder of several biotechnology companies developing therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics (traded on NASDQ, symbol BCLI), developed cell treatment for ALS patients, and is now in Phase III clinical trial.

2) In addition, we are advancing a platform for injectable CBD loaded liposomes in collaboration with Prof. Barenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem. This accurate, controlled administration of CBD by injection, is expected to be as easy as injecting insulin.

Upon every administration of CBD Oil, about 80% of the CBD is being throwed of by enzymes in the liver.  CBD Oil is not easily absorbed, only 5-10 % is ultimately being absorbed.  Patients may be overloaded to achieve a therapeutic level.

CBD is an oily molecule that normally cannot be easily injected into the body.  But once isolated inside a capsule, such as a Liposome, it could be injected.  Liposomes are small vesicles, that could entrap substance inside. The Liposomes technology is planned to enable increase bioavailability and control dosage and provide controlled release of CBD over time.

We are developing a platform for several potential indications.

For example, for people who are suffering from chronic pain, we may be able to offer an injection once a week, and over time, one could have a consistent release of CBD into the body.

Professor Barenholz has already developed a Liposome based breast cancer drug, named Doxil, that was licensed by Johnson & Johnson based on royalties from revenues.

InnoCan Pharma is collaborating with leading researchers’ leader in their fields.

This is one of few value-driven propositions of the company.

3) Innocan Pharma™ leverages extensive knowledge and understanding of the synergistic combination of CBD and FDA-Approved active ingredients for fast-acting relief of severe and acute pain.

R&G is a fast action muscle relaxant and pain relief brand and contains an analgesic blend of active ingredients with CBD. The brand provides temporary relief of muscle and joint pain.

These are EU-GMP manufactured products, clinically tested for safety

This PATENT PENDING UNIQUE FORMULATION combines the known benefits of CBD, Magnesium, Camphor and Menthol to relieve pain, help relax and recover after performing like professionals.

Combining these 4 ingredients at high concentrations, and developing a stable product is highly challenging.  So how does it work? Here is some science:

  • CBD- CBD is a potent antioxidant with anti-inflammatory properties. CBD is known to have a positive effect on pain and reduce swelling.
  • Menthol–a topical analgesic (pain reliever). Menthol produces a cooling sensation by stimulating the skin’s thermos-receptors, which send the brain a signal that is interpreted as cold, numbing effect.
  • Magnesiumchloride – is a known muscle relaxant and food supplement. We developed it into an easy-to-absorb form that may be able to raise levels of this nutrient within the body when applied topically to the skin.
    • The magnesium, absorbed through the skin, is claimed to relieve muscle pains and aches and to enhance relaxation.
  • Camphor- Assists to relieve pain and swelling and inflammation, and preventing skin redness.

4) Dermo cosmetic products powered by science, inspired by nature. SHIR, our beauty & science skincare brand combines the benefits of CBD with the most effective ingredients in innovative formulas to deliver visible fast acting results.

InnoCan Pharma has developed several premium lines of derma cosmetic products containing a tailor blend of highly concentrated ingredients, formulated with CBD. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other.

Can you describe the consumer’s behaviour towards cannabis – integrated pharmaceuticals?

As far as we know consumers are waiting to integrate Innocan Pharma’s innovation into their routine.

What challenges have you faced so far in the cannabis market and how were these overcome?

InnoCan Pharma disrupts the Cannabis world. As a pharmaceutical company, we do not grow nor extract, we focus on research and development of drug delivery platforms combining pure cannabidiol with Synergistics delivery systems of ingredients. Our challenge was to distinguish ourselves as a pharma company with highest quality standards to provide consumer confidence.

What so you see happening over the next few years regarding pharma products? What is your general prediction for the sector?

As a pharmaceutical company we predict that the Cannabis industry will move towards a much more regulated industry. Our prediction is that we will see more companies offering variety of products that combine cannabinoids among their ingredients.

What are the plans for the future and your ultimate goal?

To become a Global Leader in Cannabinoid-Integrated Pharmaceutical Products and to Improve the quality of life.

Source: https://cannabisreportworld.com/innocan-developing-revolutionary-products-that-harness-the-unique-properties-of-cannabinoids-combined-with-smart-delivery-formulations/

Innocan Pharma $INNO.ca Announces Publication of Enterprise Report by Mackie Research $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 7:17 AM on Thursday, September 3rd, 2020
Innocan-Blog

Mackie Research’s analyst, Yue (Toby) Ma, Ph.D., indicates in the updated Enterprise report that Innocan’s potential catalysts are:

  • Clinical Catalyst: Pre-clinical data of CLX in COVID-19 is expected in 9 to 12 months.
  • Licensing Catalyst: Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
  • Commercial Catalyst: Innocan’s CBD-based consumer health products are expected to be launched in several international markets in Q4 2020. The company is looking to sign more regional distribution agreements going forward.

Herzliya, Israel and Calgary, Alberta–(September 3, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that Mackie Research Capital Corporation’s institutional sales group has issued an updated Enterprise report on the Company.

The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action.

Mackie Research’s analyst, Yue (Toby) Ma, Ph.D., indicates in the updated Enterprise report that Innocan’s potential catalysts are:

  1. Clinical Catalyst: Pre-clinical data of CLX in COVID-19 is expected in 9 to 12 months.
  2. Licensing Catalyst: Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
  3. Commercial Catalyst: Innocan’s CBD-based consumer health products are expected to be launched in several international markets in Q4 2020. The company is looking to sign more regional distribution agreements going forward.

This Enterprise report is based upon general comments with no ratings and should not be construed to be a research report.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond InnoCan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the product, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in InnoCan’s public reports and filings which are available under InnoCan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. InnoCan Pharma does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

VIDEO: Innocan $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 9:31 AM on Monday, August 31st, 2020
Innocan-Blog

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The #Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $GWPH $CRDL.ca $TEVA

Posted by AGORACOM-JC at 1:54 PM on Monday, August 24th, 2020
Innocan-Blog

InnoCan – Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections 

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

WHY INNOCAN?

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
  • Separate breakthrough delivery and control release technology that enables the injection of CBD.

CONSUMER RETAIL – DERMA COSMETICS 

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements – Europe and United States
  • Manufacturing Has Commenced For 9 Products As Of Q2 2020
  • Distribution Agreements – United Kingdom and Ireland

Company entered into a distribution agreement (with a Swiss CBD provider called Cloud 9 Switzerland LLC  to sell the Company’s SHIRTM Beauty and Relief & Go product lines in Italy and Switzerland.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commence In H2 2020

     SUPERIOR MANAGEMENT TEAM

  • The InnoCan Leadership Group Is Incomparable In The Small Cap World
  • Comprised Of Leading Israeli Pharmaceutical Executives
  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
  • Together they have built a formidable team at InnoCan

SEEING IS BELIEVING

FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.

Innocan $INNO.ca to Distribute Its #CBD Line of Products in Italy and Switzerland $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:07 PM on Thursday, August 20th, 2020
Innocan-Blog
  • Entered into a distribution agreement with a Swiss CBD provider called Cloud 9 Switzerland LLC to sell the Company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland
  • Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis

Herzliya, Israel and Calgary, Alberta–(August 20, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel“) has entered into a distribution agreement (the “Agreement“) with a Swiss CBD provider called Cloud 9 Switzerland LLC (“Cloud 9“) to sell the Company’s SHIRTM Beauty and Relief & Go product lines in Italy and Switzerland.

Under the terms of the Agreement, Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis. The Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Agreement immediately, following the completion of all registration and regulatory requirements in Italy and Switzerland.



Figure 1

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/62207_556f93134488c88c_002full.jpg

“In these extraordinary times, cannabis based pharma and cosmetic products respond to consumers’ desires for a more natural and healthy lifestyle. Innocan has a proven high-level expertise and shared vision making them an ideal partner for us to develop these new markets,” said Cloud 9’s Founder and Managing Director, Dr. Francis Scanlan.

Iris Bincovich, Innocan’s Founder and CEO, commented, “We are excited to have our products distributed in Switzerland and Italy. This is the second distribution agreement we have signed in Europe. I believe Cloud 9 will provide professional distribution of our SHIR and Relief & Go product lines.”

Additionally, on July 7, 2020, the Company has engaged AGORACOM for investor awareness, marketing and branding services (the “Services“) for a 12-month online marketing campaign to engage current shareholders and the broader investment community. As consideration for the Services, Innocan will pay to AGORACOM an aggregate of $75,000 (plus applicable taxes) by way of the issuance of common shares of the Company (the “Shares“), subject to regulatory and Canadian Securities Exchange approval. The Shares are payable in five equal installments during the period from August 2020 to July 2021, as further provided for in the online marketing agreement between the Company and AGORACOM. The number of Shares to be issued under each installment will be determined by using the closing price of the common shares of Innocan on the last trading day following each period during which the Services were provided.

AGORACOM will initiate Innocan’s “HUB” which may be found at: https://agoracom.com/ir/InnocanPharma

George Tsiolis, AGORACOM’s Founder, stated, “With the cannabis markets having consolidated over the past year due to failed business plans, investors are now demanding better companies with real businesses, products, and revenues that are supported by real growth plans. Innocan checks all the boxes, with commercialization of their consumer products now commencing, as well as, a pharmaceutical division that is developing the pharmaceutical guided missile to defeat coronavirus-infected lungs. It won’t take long for the community to realize Innocan will form part of the new leadership group of cannabis driven pharmaceutical companies. We’re proud to take the Innocan story to the world.”

About Cloud 9 Switzerland LLC

The Cloud 9 Group of private companies comprises the founding company Cloud 9 Switzerland LLC, and its subsidiaries in Jamaica and France. All three are active in the health and wellness sectors, developing, producing and commercialising pharmaceuticals and nutraceuticals based on medicinal and aromatic plants – notably hemp/cannabis sativa L. Since its founding in July 2017, the group has focused on developing and commercialising premium hemp and cannabis products, building a unique portfolio of food, beverages and cosmetics; selective third party brands; and prescription and over-the-counter (OTC) medicines.

About AGORACOM

Agoracom provides online marketing, broadcasting, conferencing and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM states that it is the home of more than 7.7 million users who have visited its site 55.2 million times and read over 600 million pages of information over the last 10 years. AGORACOM further states that the average user visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

VIDEO: Innocan Pharma $INNO.ca teams up with Endless Sky to manufacturer and distribute its #CBD products $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 12:11 PM on Tuesday, August 18th, 2020
Innocan-Blog

Innocan Pharma Corporation (CSE:INNO) CEO Iris Bincovich and Endless Sky CEO Travis George tells Proactive the two have signed a manufacturing and distribution agreement.

Bincovich says Endless Sky will exclusively distribute Innocan’s CBD products in Canada and manufacture them at its Health Canada-licensed facility in Redvers, Saskatchewan.

In exchange, ESI will pay Innocan Israel a fee per product in addition to royalties based on net sales.

Source: https://ca.proactiveinvestors.com/companies/news/926966/innocan-pharma-teams-up-with-endless-sky-to-manufacturer-and-distribute-its-cbd-products-926966.html